Vitiligo treatment and therapy

Vitiligo is an acquired skin depigmentation occurring in approximately 1 percent of the population worldwide. It results from an autoimmune process directed against the melanocytes. The disease can be devastating psychologically; particularly in dark-skinned individuals. The pathogenesis is thought to involve an autoimmune process directed against melanocytes. Evidence of this is derived from histologic studies that have found an absence of melanocytes in the affected skin. An autoimmune process is also suggested by the concomitant occurrence of other autoimmune diseases in patients with vitiligo. 

  • pathogenesis of vitiligo
  • mechanism of regimentation in vitiligo
  • classification of vitiligo
  • medical treatment of vitiligo

Related Conference of Vitiligo treatment and therapy

November 17-18, 2025

8th International Dermatology Conference: Skin and Body

Paris, France
February 05-06, 2026

9th Annual Conference on Skin Cancer and Dermatology

Paris, France
April 16-17, 2026

9th World Cosmetic and Dermatology Congress

Paris, France
June 15-16, 2026

COSMETIC DERMATOLOGY 2026

Paris, France
June 22-23, 2026

28th World Dermatology and Aesthetic Congress

London, UK
August 25-26, 2026

26th European Dermatology Congress

Paris, France

Vitiligo treatment and therapy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in